Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A
Figure 2
Controlled formulation of CsA/PEG-PLGA-NPs. Correlation of NP sizes versus polymer concentrations in different organic solvents at constant ratio of volume of solvent to water. NP sizes increased from 42.3 nm to 91.4 nm as the polymer concentration increased from 1 mg/mL to 10 mg/mL in DMF. Similar trends were observed in acetone and THF (a). Correlation of NP sizes versus ratio of volume of solvent to water in different organic solvents at constant polymer concentrations (10 mg/mL) (b). The PEGylated CsA/PEG-PLGA-NPs kept their original size and remained nonaggregated for an extended period of time. However, when the non-PEGylated NPs were tested in PBS (1×), they were unstable and formed large aggregates rapidly (the particle size increased from 108.1 nm to 3223.1 nm within 1 min) (c). The size of NPs increased slightly but maintained a single distribution after lyophilization with BSA as the lyoprotectant (d).
